Por: RTTNews Health December 08, 2023
Merck & Co., Inc. (), known as MSD outside of the U.S. and Canada, and Japan's Eisai Co. Ltd. (, ESALF.PK) announced Friday that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch... + full article
ABC News USA Business December 14, 2022
Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of... + más
Merck, Moderna detail potential skin cancer vaccine progress | WPLG Local 10
Merck, Moderna detail potential skin cancer vaccine progress | Associated Press
ABC News USA Health December 14, 2022
CBS News USA Health December 14, 2022
Moderna's stock soared Tuesday after the maker detailed progress in developing a preventive shot for a deadly form of .The company said a possible vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically... + más
ABC7 USA Health December 14, 2022
.The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.The drugmakers said a combination of the vaccine and Merck's immunotherapy Keytruda led to a... + más
WPLG Local 10 USA Health December 13, 2022
Merck, Moderna detail potential skin cancer vaccine progress | ABC News
Associated Press USA Health December 13, 2022
10 WBNS USA Nation December 13, 2022
CAMBRIDGE, Mass. — Shares of Merck and Moderna jumped Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots fared well in a small study. The drugmakers said a combination of the vaccine... + más
About iurex | Privacy Policy | Disclaimer |